Table 1. Clinical and Sociodemographic Characteristics for Subsample Prescribed Obesogenic Medications.
| Weight Gain Risk | ||||||||
| Any High Risk (N = 130) |
High Risk + Bupropion (N = 31) |
High Risk Only (N = 35) |
Total (N = 1032) |
|||||
| Age (years) | ||||||||
| Mean (SD) | 49.8 (14.4) | 48.3 (12.6) | 50.4 (14.3) | 48.0 (14.5) | ||||
| Median | 52.0 | 52.0 | 53.0 | 50.0 | ||||
| Min, Max | 18, 85 | 23, 74 | 24, 74 | 18, 90 | ||||
| Age Group, N(%) | ||||||||
| 18 to 34 | 26 (20.0) | 4 (12.9) | 9 (25.7) | 227 (22.0) | ||||
| 35 to 49 | 28 (21.5) | 10 (32.3) | 5 (14.3) | 285 (27.6) | ||||
| 50 to 64 | 53 (40.8) | 14 (45.2) | 12 (34.3) | 379 (36.7) | ||||
| 65 and Over | 23 (17.7) | 3 (9.7) | 9 (25.7) | 141 (13.7) | ||||
| Sex, N(%) | ||||||||
| Female | 83 (63.8) | 21 (67.7) | 23 (65.7) | 728 (70.5) | ||||
| Male | 47 (36.2) | 10 (32.3) | 12 (34.3) | 304 (29.5) | ||||
| Ethnicity, N(%) | ||||||||
| Hispanic or Latino | 8 (6.2) | 2 (6.5) | 4 (11.4) | 80 (7.8) | ||||
| Not Hispanic or Latino | 122 (93.8) | 29 (93.5) | 31 (88.6) | 952 (92.2) | ||||
| Race, N(%) | ||||||||
| White | 111 (85.4) | 25 (80.6) | 29 (82.9) | 838 (81.2) | ||||
| Black | 16 (12.3) | 5 (16.1) | 5 (14.3) | 151 (14.6) | ||||
| Asian | 2 (1.5) | 1 (3.2) | 0 | 19 (1.8) | ||||
| Other or Multiple | 1 (0.8) | 0 | 1 (2.9) | 24 (2.3) | ||||
| Annual Income ($), N(%) | ||||||||
| 0–25,000 | 47 (36.2) | 13 (41.9) | 10 (28.6) | 442 (42.8) | ||||
| 25,000–50,000 | 42 (32.3) | 11 (35.5) | 12 (34.3) | 253 (24.5) | ||||
| 50,000–75,000 | 12 (9.2) | 3 (9.7) | 5 (14.3) | 117 (11.3) | ||||
| 75,000–100,000 | 7 (5.4) | 1 (3.2) | 2 (5.7) | 52 (5.0) | ||||
| 100,000 and above | 5 (3.8) | 1 (3.2) | 2 (5.7) | 35 (3.4) | ||||
| Refused to answer | 17 (13.1) | 2 (6.5) | 4 (11.4) | 133 (12.9) | ||||
| Highest Level of Education, N(%) | ||||||||
| Less than high school | 6 (4.7) | 3 (10.0) | 0 | 34 (3.3) | ||||
| High school diploma or equivalent | 23 (18.0) | 3 (10.0) | 6 (17.6) | 212 (20.9) | ||||
| Some college or postsecondary, no degree | 32 (25.0) | 11 (36.7) | 6 (17.6) | 252 (24.8) | ||||
| Associate’s degree | 18 (14.1) | 4 (13.3) | 4 (11.8) | 128 (12.6) | ||||
| Bachelor’s degree | 32 (25.0) | 7 (23.3) | 11 (32.4) | 246 (24.2) | ||||
| Master’s degree | 15 (11.7) | 2 (6.7) | 7 (20.6) | 109 (10.7) | ||||
| Doctoral or professional degree | 2 (1.6) | 0 | 0 | 34 (3.3) | ||||
| Smoker, N(%) | ||||||||
| No | 100 (76.9) | 27 (87.1) | 28 (80.0) | 872 (84.5) | ||||
| Yes | 30 (23.1) | 4 (12.9) | 7 (20.0) | 160 (15.5) | ||||
| Generalized Anxiety Disorder Diagnosis, N(%) | ||||||||
| 0 | 99 (76.2) | 22 (71.0) | 28 (80.0) | 864 (83.8) | ||||
| 1 | 31 (23.8) | 9 (29.0) | 7 (20.0) | 167 (16.2) | ||||
| Panic Disorder Diagnosis, N(%) | ||||||||
| 0 | 100 (76.9) | 22 (71.0) | 32 (91.4) | 873 (84.7) | ||||
| 1 | 30 (23.1) | 9 (29.0) | 3 (8.6) | 158 (15.3) | ||||
| Posttraumatic Stress Disorder Diagnosis, N(%) | ||||||||
| 0 | 119 (91.5) | 27 (87.1) | 34 (97.1) | 980 (95.1) | ||||
| 1 | 11 (8.5) | 4 (12.9) | 1 (2.9) | 51 (4.9) | ||||
| Depression Category, N(%) | ||||||||
| Moderate (HAM-D17 14–18) | 25 (19.2) | 8 (25.8) | 5 (14.3) | 289 (28.0) | ||||
| Severe (HAM-D17 19–22) | 45 (34.6) | 12 (38.7) | 10 (28.6) | 373 (36.1) | ||||
| Very Severe (HAM-D17 > 23) | 60 (46.2) | 11 (35.5) | 20 (57.1) | 370 (35.9) | ||||
| Baseline HAM-D17 | ||||||||
| Mean (SD) | 22.0 (4.0) | 21.2 (3.5) | 23.1 (4.5) | 21.2 (4.2) | ||||
| Median | 22.0 | 20.0 | 24.0 | 21.0 | ||||
| Min, Max | 14, 33 | 15, 27 | 14, 33 | 14, 37 | ||||
| Prior Medication Trials Without Response | ||||||||
| Mean (SD) | 3.9 (2.9) | 4.5 (3.3) | 3.8 (3.4) | 3.0 (2.3) | ||||
| Median | 3.0 | 4.0 | 3.0 | 2.0 | ||||
| Min, Max | 1, 18 | 1, 18 | 1, 13 | 1, 18 | ||||
| Number of Comorbidities | ||||||||
| Mean (SD) | 7.8 (6.0) | 8.5 (5.1) | 7.6 (7.9) | 7.0 (5.5) | ||||
| Median | 7.0 | 9.0 | 6.0 | 6.0 | ||||
| Min, Max | 0, 45 | 2, 24 | 0, 45 | 0, 47 | ||||
| Baseline Weight (pounds) | ||||||||
| Mean (SD) | 183.2 (40.6) | 188.8 (36.0) | 171.8 (37.0) | 193.3 (49.8) | ||||
| Median | 185.2 | 190.0 | 176.0 | 186.0 | ||||
| Min, Max | 103, 300 | 130, 271 | 108, 280 | 95, 387 | ||||
The following table details features for patients with mdd on “high risk” medications, alone, or with adjunctive “no risk” bupropion to test the hypothesis of whether bupropion appears to mitigate risk of weight gain. As illustrated in figure 1, these groupings are not mutually exclusive as those in the “high risk only” and “high risk + no risk” categories are also included in the “any high risk” group.